Evicenter
MarkdownMedical informationP&T meetings
Descartes-08

Generalized myasthenia gravis

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

10 evidence topics · 12 sources

Summary
  • Refractory disease: Refractory MG has been defined as a post-intervention status unchanged or worse after corticosteroids and at least 2 other immunosuppressive agents used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning. An estimated 10% to 20% of patients continue to have long-standing moderate or severe weakness after treatment with at least two different immunosuppressive drugs at high doses, and about 20,000 patients with generalized MG are estimated to be intolerant of or to have an inadequate response to conventional treatment.
  • Incomplete response to targeted biologics: Upward of thirty percent of patients do not benefit from complement inhibition. No head-to-head prospective studies have compared the novel therapies; in one analysis, FcRn inhibitors carried greater odds of treatment-related adverse events than placebo (odds ratio 2.20 [1.52-3.38]), while C5 inhibitors and CD19+ B-cell depletion showed odds comparable to placebo.
  • Glucocorticoid toxicity: Incident glucocorticoid toxicities occurred in 61.9% of patients with any glucocorticoid use and 52.3% of those without; common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection, and chronic toxicities included dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension. Toxicities and costs tended to increase with increasing glucocorticoid use.
  • Infection risk and REMS: Eculizumab, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis, meningococcal vaccination is required at least 2 weeks before the first dose of eculizumab, and eculizumab and zilucoplan are available only through restricted REMS programs. One case of meningococcal meningitis occurred despite vaccination in the eculizumab open-label extension. In Study 1 of efgartigimod, urinary tract infections occurred in 10% of efgartigimod-treated and 5% of placebo-treated patients, and respiratory tract infections in 33% and 29%.
  • Administration burden: Reported limitations include the need for meningococcal vaccination and regular intravenous or subcutaneous injections; eculizumab is infused intravenously over 35 minutes in adults, and the safety of starting rozanolixizumab cycles sooner than 63 days after the start of the previous cycle has not been established. Current targeted therapies generally require lifelong repeated administration and “rarely induce durable treatment-free remission”.
  • Cost: In one cost-effectiveness analysis, eculizumab at an estimated annual cost of $653,100 had an incremental cost-effectiveness ratio of $5,210,000 per QALY/evLYG, and efgartigimod at a placeholder price of $418,400 had $2,076,000 per QALY/evLYG. Very high drug costs have limited access to complement and FcRn inhibitors in most countries. Annual all-cause costs were $76,381 among patients with any glucocorticoid use and $35,309 among those without.
Meningococcal infection risk, vaccination, and REMS with complement C5 inhibitors